+

WO2003018035A1 - Preparation pharmaceutique pour le traitement de blessures - Google Patents

Preparation pharmaceutique pour le traitement de blessures Download PDF

Info

Publication number
WO2003018035A1
WO2003018035A1 PCT/DE2002/002910 DE0202910W WO03018035A1 WO 2003018035 A1 WO2003018035 A1 WO 2003018035A1 DE 0202910 W DE0202910 W DE 0202910W WO 03018035 A1 WO03018035 A1 WO 03018035A1
Authority
WO
WIPO (PCT)
Prior art keywords
component
preparation according
solution
per liter
growth factor
Prior art date
Application number
PCT/DE2002/002910
Other languages
German (de)
English (en)
Inventor
Thomas Riesinger
Original Assignee
Nawa-Heilmittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nawa-Heilmittel Gmbh filed Critical Nawa-Heilmittel Gmbh
Publication of WO2003018035A1 publication Critical patent/WO2003018035A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]

Definitions

  • the invention relates to a pharmaceutical preparation or to a pharmaceutical preparation for the treatment of wounds.
  • a preparation which contains as an active ingredient a growth factor produced on the basis of platelets, which is also known to experts under the name PDGF (platelet derived grwoth factor) (US Pat. No. 5,457,093).
  • PDGF platelet derived grwoth factor
  • Regranex namely as a gel with 0.01% (weight percent) active ingredient.
  • the object of the present invention is to show a pharmaceutical preparation which enables a substantially improved care of wounds, including acute or chronic wounds.
  • a pharmaceutical preparation is designed according to claim 1.
  • the “growth factor PDGF” is generally a growth factor produced on the basis of platelets.
  • the preparation according to the invention consists, for example, of a mixture of at least a first component which contains the growth factor PDGF and a second component in the form of an aqueous solution which, in addition to distilled water, contains at least zinc, iron and a proportion of acid, preferably sulfuric acid.
  • the proportion of acid in the second component is chosen such that the latter has a pH between 2.5 and 3.5, preferably a pH of 2.8.
  • the proportion or mixture ratio between the first component and the second component is selected such that the combination of the two components results in a pH value which is in any case in the acidic range, ie less than 7.
  • the second component is produced in such a way that this component in aqueous solution contains 10-100 mg Zn and 6.5-65 mg Fe per liter of distilled water, the proportion of sulfuric acid (H 2 S0 4 95-97% - ig) is selected so that the pH value is between 2.5 and 3.5, preferably the pH value of 2.8.
  • ZnCI 2 and FeS0 4 are particularly suitable as raw or starting materials, namely about 20-209 mg ZnCI and 32-325 mg FeS0 4 per liter of solution.
  • a possible composition for the second component then contains per liter
  • the pharmaceutical composition according to the invention has a significantly improved healing effect, both in comparison to the 0.01% gel "Regranex" containing the growth factor and in particular also in comparison to wound healing without using the Gel and the composition according to the invention
  • Treatment with the preparation according to the invention resulted in 100% healing in almost all experimental animals
  • Experiments were carried out on superficial wounds, ie on wounds with a depth of up to 0.3 mm and with five wounds per experimental animal. The results of the tests are shown in the tables below in:
  • Table 3 wound healing when treating the wounds with the preparation according to the invention in the aforementioned special composition of the second component, which contains 30 mg Zn and 20 mg Fe per liter of solution.
  • the numbers in the tables indicate the number of wounds healed in relation to the total number of five wounds on an animal.
  • the percentages relate to the degree of wound healing, with complete healing being indicated in 100%.
  • the results of Tables 1-3 are shown again in the graphs of FIGS. 1-3, namely the duration of wound healing in days and the degree of healing in%, up to a 100% healing of the wounds, in FIG. 1 for treatment of wounds treated neither with the product “Regranex” nor with the preparation according to the invention,
  • the increased effect of the composition according to the invention is obviously due to the fact that the acid in connection with the iron of the second component has bacterostatic properties, i.e. this creates a milieu that prevents the growth of germs and bacteria and has a repulsive effect on them, so that inflammation caused by germs entering the wound and developing there is effectively prevented.
  • the acidic environment based on the second component optimizes the wound environment as a whole and stimulates the metabolism in the surrounding tissue, so that the effects of the growth factor PDGF can develop fully.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une nouvelle préparation pharmaceutique destinée au traitement de blessures, laquelle comprend une proportion de facteur de croissance dérivé des plaquettes (PDGF).
PCT/DE2002/002910 2001-08-18 2002-08-08 Preparation pharmaceutique pour le traitement de blessures WO2003018035A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2001140623 DE10140623A1 (de) 2001-08-18 2001-08-18 Pharmazeutisches Präparat zur Behandlung von Wunden
DE10140623.1 2001-08-18

Publications (1)

Publication Number Publication Date
WO2003018035A1 true WO2003018035A1 (fr) 2003-03-06

Family

ID=7695918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/002910 WO2003018035A1 (fr) 2001-08-18 2002-08-08 Preparation pharmaceutique pour le traitement de blessures

Country Status (2)

Country Link
DE (1) DE10140623A1 (fr)
WO (1) WO2003018035A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034321A2 (fr) * 2005-09-26 2007-03-29 Biodex Compositions pharmaceutiques a activite cicatrisante comprenant au moins un derive de dextrane soluble et au moins un facteur de croissance derive des plaquettes

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007044202A1 (de) 2007-09-17 2009-03-19 Deckner, Peter G., Dr. med. Zusammensetzung für Wundbehandlungen
DE102007044583A1 (de) 2007-09-19 2009-04-09 Deckner, Peter G., Dr. med. Zusammensetzung für Wundbehandlungen im Veterinärbereich
DE102007044582A1 (de) 2007-09-19 2009-04-09 Deckner, Peter G., Dr. med. Zusammensetzung für Wundbehandlungen im Humanbereich

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
WO1997012601A2 (fr) * 1995-10-06 1997-04-10 Ethicon, Inc. Formulations de gel contenant des facteurs de croissance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
WO1997012601A2 (fr) * 1995-10-06 1997-04-10 Ethicon, Inc. Formulations de gel contenant des facteurs de croissance

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034321A2 (fr) * 2005-09-26 2007-03-29 Biodex Compositions pharmaceutiques a activite cicatrisante comprenant au moins un derive de dextrane soluble et au moins un facteur de croissance derive des plaquettes
FR2891149A1 (fr) * 2005-09-26 2007-03-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
WO2007034321A3 (fr) * 2005-09-26 2007-10-04 Biodex Compositions pharmaceutiques a activite cicatrisante comprenant au moins un derive de dextrane soluble et au moins un facteur de croissance derive des plaquettes

Also Published As

Publication number Publication date
DE10140623A1 (de) 2003-03-06

Similar Documents

Publication Publication Date Title
DE60012610T2 (de) Selektive antibakterielle Zusammensetzunge
DE3606735A1 (de) Verfahren zur herstellung von stabilen ozonisierten oelen aus ungesaettigten pflanzenoelen
WO2003018035A1 (fr) Preparation pharmaceutique pour le traitement de blessures
DE60006432T2 (de) Verfahren zur Herstellung einer aromatischen antibakteriellen Zubereitung enthaltend Hinokitiol
DD265387A5 (de) Stabilisierte waessrige wasserstoffperoxidzusammensetzung
WO2000025763A2 (fr) Agents exerçant un effet inhibiteur de proliferation sur des cellules tumorales
DE69206398T2 (de) Reichstoffzusammensetzungen.
DE102019006848A1 (de) Creme zur äußeren Anwendung auf der Haut im Brust-, Bauch-, Rücken- und Unterleibsbereich zur Linderung von Menstruationsbeschwerden
DE960579C (de) Verfahren zur Herstellung eines in der Hitze sterilisierbaren Adrenocorticotropin-Praeparates
DE3541814A1 (de) Desinfizierende sruehzusammensetzung
DE19922932B4 (de) Kosmetisches Präparat und Verfahren zu seiner Herstellung
DE102006060159B4 (de) Repellent für Pferde
AT155970B (de) Insektenvertilgungsmittel.
DE1767616C (de) Heilmittel gegen Nosema und Milben bei Bienen, sowie Verfahren zu seiner Her Stellung
DE2637363A1 (de) Verfahren zur herstellung einer bakteriziden verbindung
DE831126C (de) Verfahren zur Erzeugung antibakterieller Wirkstoffe
DE202021105961U1 (de) Eine pflanzliche Gel-Zusammensetzung
AT251969B (de) Fungizide Zusammensetzung mit Aktivität gegen Oidium
Kato Experimentelle Untersuchungen an den Herzmuskelfasern.
DE102022107833A1 (de) Repellierende Zusammensetzung und deren Verwendung
DE202006003249U1 (de) Chitin-, Glucan-, Melanin Wundpuder (CGM Wundpuder)
DE102021124078A1 (de) Kosmetikzusammensetzung zur Anwendung auf der Haut
CH686659A5 (de) Mittel zur Behandlung und Preventivpflege von Hufen.
AT56857B (de) Verfahren zur Herstellung von Mitteln gegen Pflanzenschädlinge.
DE202023102783U1 (de) Zusammensetzung einer antibakteriellen Lotion mit Zitronengrasöl, angereichert mit Bioaktivstoffen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DK DZ EC EE ES FI GB GD GE GH GM HR ID IL IN IS JP KE KG KP KR KZ LC LK LS LT LU LV MA MD MG MK MN MW MZ NO NZ OM PH PL PT RO RU SD SE SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载